Silexion Therapeutics Corp [NASDAQ: SLXN] stock went on an upward path that rose over 20.42% on Wednesday, amounting to a one-week price increase of more than 17.00%.
Over the last 12 months, SLXN stock dropped by -90.41%. The one-year Silexion Therapeutics Corp stock forecast points to a potential upside of 75.92. The average equity rating for SLXN stock is currently 1.00, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $9.03 million, with 3.13 million shares outstanding and 2.31 million shares in the current float. Compared to the average trading volume of 472.48K shares, SLXN stock reached a trading volume of 155260 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Silexion Therapeutics Corp [SLXN]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SLXN shares is $12.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SLXN stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
The Price to Book ratio for the last quarter was 1.30, with the Price to Cash per share for the same quarter was set at 2.97.
SLXN Stock Performance Analysis:
Silexion Therapeutics Corp [SLXN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 17.00. With this latest performance, SLXN shares dropped by -15.74% in over the last four-week period, additionally sinking by -79.93% over the last 6 months – not to mention a drop of -90.41% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SLXN stock in for the last two-week period is set at 48.32, with the RSI for the last a single of trading hit 0.28, and the three-weeks RSI is set at 0.30 for Silexion Therapeutics Corp [SLXN]. The present Moving Average for the last 50 days of trading for this stock 3.30, while it was recorded at 2.42 for the last single week of trading, and 10.40 for the last 200 days.
Silexion Therapeutics Corp (SLXN) Capital Structure & Debt Analysis
According to recent financial data for Silexion Therapeutics Corp. ( SLXN), the Return on Equity (ROE) stands at -771.23%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -125.80%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Silexion Therapeutics Corp’s Return on Invested Capital (ROIC) is -104.75%, showcasing its effectiveness in deploying capital for earnings.
Silexion Therapeutics Corp (SLXN) Efficiency & Liquidity Metrics
Based on Silexion Therapeutics Corp’s (SLXN) latest financial statements, the Debt-to-Equity Ratio is 0.29%, indicating its reliance on debt financing relative to shareholder equity.
Silexion Therapeutics Corp (SLXN) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Silexion Therapeutics Corp. (SLXN) effectively leverages its workforce, generating an average of -$660714.29 per employee. The company’s liquidity position is robust, with a Current Ratio of 3.97% and a Quick Ratio of 3.97%, indicating strong ability to cover short-term liabilities.
SLXN Stock EPS
With the latest financial reports released by the company, Silexion Therapeutics Corp posted -2.88/share EPS, while the average EPS was predicted by analysts to be reported at -3.4/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.52. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SLXN. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Silexion Therapeutics Corp go to 77.13%.
Silexion Therapeutics Corp [SLXN] Institutonal Ownership Details
There are presently around $8.49%, or 8.90%% of SLXN stock, in the hands of institutional investors.
